Bristol-Myers Squibb, in partnership with K36 Therapeutics, updated progress on their Phase 1 trial of KTX-1001 for relapsed ...

This was the stock's third consecutive day of gains.

Patients with stage III melanoma were treated with nivolumab (anti-PD1) and relatlimab (anti-LAG-3) before surgery87% of ...

The drug, which Repare recently sidelined, has shown promising activity in a patient with ALT-positive melanoma that researchers want to study in others.

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

The number of employees laid off and companies letting people go increased year over year during the first half of 2025. BioSpace recaps the five largest layoff rounds, including cuts at Bayer, BMS ...

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...

Bristol Myers Squibb outperformed major indexes, closing 1.32% higher at $47.66, while peers lagged. The company’s stock ...

In the latest trading session, Bristol Myers Squibb (BMY) closed at $47.66, marking a +1.32% move from the previous day. This change outpaced the S&P 500's 0.61% gain on the day. Elsewhere, the Dow ...

During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in ...

Skadden partner Joseph Barloon, former Jones Day partner Brett Shumate and former Wilmer partner Jeffrey Kessler, among ...